CEL-SCI Corporation — Form 10-K Summary
Reporting period: Fiscal year ended September 30, 2012. The filing also reports the fourth quarter ended September 30, 2012. CEL-SCI is a development-stage biotechnology company; it reported no product-sale revenue.
Business context and development
The lead candidate, Multikine, was being studied in a global Phase III trial for previously untreated, advanced head and neck cancer. The trial’s primary endpoint is a 10% improvement in overall survival versus standard care alone. Of 48 planned trial sites, 36 had completed site-initiation visits, with patients being screened or enrolled. An independent data monitoring committee’s interim safety review identified no safety concerns; it did not establish efficacy.
Other programs included LEAPS-based candidates for pandemic influenza and rheumatoid arthritis, which remained preclinical or otherwise early-stage. None of CEL-SCI’s candidates was approved for sale. The company also had a validated manufacturing facility for Multikine.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Grant income and other revenue | $254,610 | $956,154 |
| Research and development expense | $10,368,695 | $11,745,629 |
| Total operating expenses | $17,497,450 | $18,941,828 |
| Operating loss | $17,242,840 | $17,985,674 |
| Net loss | $15,477,310 | $25,712,343 |
| Net loss available to common shareholders | $17,645,930 | $26,780,712 |
| Basic loss per share | $0.07 | $0.13 |
| Operating cash used | $12,190,013 | $22,555,411 |
Revenue was primarily grant-related, not product sales. Operating margins are not meaningful given the absence of product revenue and the company’s development-stage operations. The FY 2012 net loss included a $1.9 million noncash gain on derivative instruments; changes in derivative fair value drove substantial quarterly earnings fluctuations.
At September 30, 2012, cash and cash equivalents were $3.94 million, working capital was $5.53 million, total assets were $16.07 million, and total liabilities were $9.04 million. Stockholders’ equity was $7.03 million. CEL-SCI had $6.98 million of derivative liabilities, primarily related to warrants. The $5.0 million settlement-related convertible notes were repaid by March 2012; a $1.10 million loan from the president remained outstanding, bearing 15% interest and secured by company assets.
FY 2012 financing provided $12.00 million net cash: $14.29 million from common-stock issuance and $2.66 million from warrant and option exercises, offset by $4.95 million of convertible-debt repayment. The company reported a $0.32 million decrease in cash for the year. It raised an additional $10.5 million in a registered offering on December 4, 2012, before filing. Management stated it believed available capital would support operations for more than 12 months, while also saying further financing would be needed to continue research and complete the trial.
Material changes and unusual items
- Annual net loss narrowed by about $10.2 million, mainly because FY 2011 included a $12.0 million charge related to settlement of litigation. The settlement required $3.0 million cash and $9.0 million of securities; the notes were repaid and preferred shares redeemed by 2012.
- Grant income fell by $701,544, including because the company received the final funds for the prior grant in October 2011. R&D expense fell by about $1.38 million, with spending varying according to trial activity.
- Common shares outstanding increased from 214.7 million to 273.1 million during FY 2012. The December 2012 offering added 35 million shares and included warrants for up to 26.25 million additional shares.
- FY 2012 quarterly results were uneven: fourth-quarter revenue was $108,043 and net loss was $2,566,692, compared with $172,118 revenue and $2,317,532 net loss in FY 2011’s fourth quarter.
Outlook, risks, and commitments
CEL-SCI estimated the Multikine Phase III trial’s net cost, excluding portions funded by licensees, at approximately $32 million, with about $7 million paid by September 30, 2012. The filing separately estimated approximately $25 million in remaining vendor obligations for trial work. Management cautioned that costs could exceed estimates and depend on enrollment, foreign exchange, and other factors. Teva and Orient Europharma had agreed to fund portions of trial activity in their territories.
The company expected continued losses and could not predict when, or whether, product revenue would begin. It said it would need additional capital through equity, debt, partnerships, warrant or option exercises, or other financing; unavailable or unfavorable financing could delay or curtail the trial. Other material risks include clinical-trial failure or delay, regulatory rejection, competition, dilution, derivative-liability volatility, and product-liability and manufacturing risks. Operating lease commitments totaled $32.20 million, including the long-term manufacturing-facility lease. No common-stock dividends were planned.
Management reported effective disclosure controls and internal control over financial reporting as of September 30, 2012. BDO USA, LLP issued unqualified audit opinions on the financial statements and internal controls.
Important facts for investors to verify
- Current Phase III enrollment, site status, trial timeline, endpoint analysis plan, and any subsequent safety or efficacy disclosures.
- Actual remaining trial costs and licensee contributions versus the stated estimates; cash runway after the December 2012 financing.
- Fully diluted share count, outstanding warrants and options, and potential dilution from financing instruments.
- Valuation and future earnings effects of the $6.98 million derivative liabilities, which are based on fair-value estimates.
- Terms, maturity, collateral, and repayment status of the related-party loan, along with lease and trial-vendor obligations.